Topic resource collection
Approved comparison material connected to this topic.
95 resourcesRead both sides
A Phase 2 clinical trial published in Nature Medicine in 2024 found that a peptide showing remarkable neuroprotective effects in mice. Reducing cognitive decline markers by 65%. Produced only 8% improvement in human participants …
The table below compares VIP's neuroprotective efficacy across common preclinical models, highlighting delivery routes, dose ranges, and therapeutic windows that define successful outcomes. MPTP Parkinson's Model Intranasal 50–20…
Before diving into mechanistic details, it's useful to understand how Thymalin immune aging research compares to alternative approaches targeting immunosenescence. Each operates through distinct pathways with different evidence l…
Batch Allocation Priority General inventory only 15% reserved allocation 20% reserved allocation + same-batch guarantees 25% reserved allocation + custom batch requests Tier 2+ eliminates protocol disruption from supply variance.…
To make the distinctions clearer, here’s a simple breakdown our team put together: Primary Focus Localized Tissue Repair Systemic Healing & Anti-Inflammatory Support Origin Synthetic fragment of a gastric protein Synthetic fragme…
Syringes Luer-lock polypropylene, 1mL and 3mL, sterile single-use Luer-lock polypropylene with printed graduation marks certified to ±2% accuracy Research syringes lack volumetric certification Clinical syringes are required for …
Survodutide Phase 3 NASH, Obesity 48% histological NASH resolution vs 12% placebo; 52% liver fat reduction 72 weeks p<0.001 for primary endpoint First dual-agonist to achieve fibrosis improvement in Phase 3. Regulatory filing exp…
Mitochondrial-targeting (SS-31 analogs) Cardiolipin binding, cristae stabilization Subcutaneous injection FDA-approved (Nov 2026) Blood-brain barrier penetration previously thought impossible First mitochondrial peptide to achiev…
Triple Receptor Agonist GLP-1/GIP/Glucagon 24.7% weight loss at 28 weeks (vs 20.9% tirzepatide baseline) Glucagon engagement drives thermogenesis without muscle catabolism Obesity + T2DM treatment ceiling raised significantly Thi…
Nature Neuroscience, July 8 Stanford Medicine Dihexa HGF pathway activation at 0.5 mg/kg protects dopaminergic neurons from oxidative stress Neuroprotection occurs at 40% lower concentration than cognitive enhancement threshold. …
CNS-Active Peptides Stanford, Johns Hopkins, UC San Diego Lipidated Dihexa analogues: 4.2× BBB penetration; cerebrolysin mechanism mapped; P21 cognitive improvement in MCI Phase 2 (P21 complete); Phase 1 (lipidated Dihexa analogu…
The following table summarizes the three major peptide categories that dominated September 2026 research developments, their mechanisms, clinical milestones, and research implications. Dual-Receptor Metabolic Agonists Survodutide…
Survodutide GLP-1/glucagon dual agonist 18.6% mean body weight reduction at 72 weeks; 12–14% RMR increase sustained without appetite escalation Adults with obesity (BMI ≥30) or overweight with comorbidity Phase 3 (SYNCHRONIZE tri…
Tirzepatide GIP/GLP-1 dual agonist 23.1% body weight reduction 104 weeks Exceeds single-pathway GLP-1 outcomes by 35–40%; rivals bariatric surgery without invasion Survodutide GLP-1/glucagon dual agonist 18.7% weight loss, 92% le…
Before selecting peptides for metabolic, cognitive, or immune research protocols, understanding mechanism-specific advantages across compound classes prevents mismatched applications and wasted resources. Survodutide Dual GLP-1/g…
KPV (tripeptide) I B stabilization. Prevents NF- B nuclear translocation Direct transcription inhibition Receptor-independent (passive diffusion) Minimal. Compartmentalized effect Broad (any cell expressing NF- B pathway) Cortico…
KPV (investigational) NF-κB translocation inhibition 40–60% TNF-α, 50–70% IL-6 (in vitro) Unknown. Preclinical only Not established Research-grade compound with upstream anti-inflammatory action; no human safety or efficacy data …
Administration Schedule 5mg/kg SC daily × 10 days 10mg/kg SC daily × 14 days 10mg/kg SC single dose Extended dosing required for measurable thymic weight increase. Single-dose protocols consistently fail to reach significance Mea…
Cell culture receptor binding assay 1–50 µM in culture medium Direct application to cells Receptor occupancy via fluorescence 30 min – 6 hours Gold standard for mechanism studies; high control, low complexity In vitro metabolic p…
Cartalax operates through a fundamentally different biological pathway than conventional joint pain treatments. Where NSAIDs inhibit cyclooxygenase enzymes to reduce prostaglandin-mediated inflammation and corticosteroids suppres…